Recent Announcements
PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider
Veteran leaders join to accelerate commercialization and market access strategy as the company...
PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Original Press Release Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200...
PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial
Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and...
PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today...
Featured Article
Innovations in Parkinson’s Treatment: Exploring Light Therapy and Beyond – Part-2
Introduction Welcome back to our exploration of groundbreaking advancements in Parkinson's Disease (PD) treatment. In Part 1, we dived into the potential of light therapy, other innovative non-pharmacological approaches like Focused Ultrasound and Transcranial...
Innovations in Parkinson’s Treatment: Exploring Light Therapy and Beyond – Part-2
Introduction Welcome back to our exploration of groundbreaking advancements in Parkinson's Disease (PD) treatment. In Part 1, we dived into the potential of light therapy, other innovative non-pharmacological approaches like Focused Ultrasound and Transcranial...
Archived Content